Title 19 Promis's Form 4 filing
ProMIS Neurosciences Inc. (PMN) · filed Jul 29, 2025
- Accession no.
- 0001104659-25-071857
- Filed
- Jul 29, 2025
- Trade date
- Jul 25-29, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 4 derivative transactions. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001104659-25-078637 (Aug 14, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Title 19 PromisCIK 0002005531 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 25, 2025 | Common Shares, no par value | XIn-the-money exerciseAcquired | +119,800 | –F1 | – | 2,195,429 | Direct | |
| Jul 25, 2025 | Common Shares, no par value | XIn-the-money exerciseAcquired | +119,800 | –F2 | – | 2,315,229 | Direct | |
| Jul 25, 2025 | Common Shares, no par value | XIn-the-money exerciseAcquired | +119,800 | –F3 | – | 2,435,029 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 25, 2025 | Common Shares | XIn-the-money exerciseDisposed | −119,800 | $0.00 | $0 | 345,316 | Direct | |
| Jul 25, 2025 | Common Shares | XIn-the-money exerciseDisposed | −119,800 | $0.00 | $0 | 345,316 | Direct | |
| Jul 25, 2025 | Common Shares | XIn-the-money exerciseDisposed | −119,800 | $0.00 | $0 | 345,316 | Direct | |
| Jul 29, 2025 | Common Shares | PPurchaseAcquired | +539,100 | –F4 | – | 539,100 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
Referenced by the price of 1 transaction in Table I.
- F2
On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
Referenced by the price of 1 transaction in Table I.
- F3
On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.
Referenced by the price of 1 transaction in Table I.
- F4
On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.
Referenced by the price of 1 transaction in Table II.